ACTU Projected Dividend Yield
Actuate Therapeutics Inc ( NASDAQ : ACTU )Actuate Therapeutics is a clinical stage biopharmaceutical company that engaged in the developing therapies for the treatment of cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). Co. is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3ß, thereby causing the death of the cancer cells and the regulation of anti-tumor immunity. Co. operates as a semi-virtual biopharmaceutical company with expertise in all aspects of preclinical and clinical development. 21 YEAR PERFORMANCE RESULTS |
ACTU Dividend History Detail ACTU Dividend News ACTU Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |